Related Experiment Video
Updated: Jul 4, 2026
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Clinical investigations of Toll-like receptor agonists
Thomas Meyer1, Eggert Stockfleth
1University of Hamburg, University Hospital Hamburg-Eppendorf, Institute of Medical Microbiology, Virology and Hygiene, Martinistrasse 52, 20246 Hamburg, Germany. th.meyer@uke.de
Background:
Toll-like receptors (TLR) represent a family of surface molecules that function as primary sensors of the innate immune system to recognize microbial pathogens. Ligand binding to TLR results in activation of cellular signaling pathways that regulate expression of genes involved in inflammation and immunity.
Objective:
Use of synthetic TLR ligands (agonists) for treatment and prevention of infectious and neoplastic diseases.
Methods:
Review of literature about clinical investigations of agonists of TLR 4, 7, 8, and 9.
Results/Conclusions:
Imiquimod was the first TLR agonist approved for treatment of anogenital warts, actinic keratosis and superficial basal cell carcinoma in humans. Several other agonists of TLRs 4, 7, 8 and 9 were also shown to be effective for treatment of infections and cancers and, furthermore, were used as adjuvants for vaccination. Based on safety and efficacy of the TLR agonists used to date, applications are likely to increase in the future.
Insights
Synthetic Toll-like receptor (TLR) agonists show promise in treating infections and cancers. These immune system modulators are effective as standalone therapies and vaccine adjuvants, with expanding future applications.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- Toll-like receptors (TLRs) are key sensors of the innate immune system.
- TLR activation triggers signaling pathways regulating inflammation and immunity.
- They recognize microbial pathogens, initiating immune responses.
Purpose of the Study:
- To review clinical investigations of synthetic Toll-like receptor (TLR) agonists.
- To evaluate the therapeutic potential of TLR agonists in infectious and neoplastic diseases.
- To explore the use of TLR agonists as vaccine adjuvants.
Main Methods:
- Literature review of clinical studies.
- Focus on agonists targeting TLR 4, 7, 8, and 9.
- Analysis of safety and efficacy data.
Main Results:
- Imiquimod, a TLR agonist, is approved for treating warts and skin cancers.
- Other TLR agonists (TLR 4, 7, 8, 9) demonstrate efficacy against infections and cancers.
- TLR agonists are effective as adjuvants in vaccination.
Conclusions:
- Synthetic TLR agonists represent a valuable therapeutic class.
- Their applications in treating infections, cancers, and enhancing vaccines are expanding.
- Future therapeutic strategies will likely leverage TLR agonist properties.
